Healios KK (4593) Price & Analysis

Compare

6 Followers

4593 Stock Chart & Stats

¥304.00

¥3.00(1.60%)

At close: Jan 08 4:00 PM EST

¥304.00

¥3.00(1.60%)

Day’s Range― - ―

52-Week Range¥194.00 - ¥747.00

Previous CloseN/A

Volume811.70K

Average Volume (3M)1.65M

Market Cap

¥56.70B

Enterprise Value¥49.32B

Total Cash (Recent Filing)¥5.68B

Total Debt (Recent Filing)¥3.04B

Price to Earnings (P/E)―

Beta1.13

Next Earnings

May 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)18.90

Shares Outstanding135,002,200

10 Day Avg. Volume1,843,110

30 Day Avg. Volume1,654,023

Financial Highlights & Ratios

PEG Ratio0.23

Price to Book (P/B)6.03

Price to Sales (P/S)283.63

P/FCF Ratio-8.85

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

¥800.00

Price Target Upside163.16% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-47.95

Revenue Forecast (FY)¥1.03B

Bulls Say, Bears Say

Bulls Say

Improved Leverage / Stronger Capital StructureA materially lower debt-to-equity ratio reduces near-term solvency pressure and interest burden, increasing financial flexibility for multi-year R&D programs. This improves the company's ability to fund trials or partnerships without immediate dilutive financing, a durable balance-sheet improvement.

Specialized Regenerative Medicine FocusA focused business model in cell therapy and iPSC-related approaches targets high unmet medical needs with substantial entry barriers. Sustained expertise and external collaborations can create durable competitive moats, de-risk commercialization, and provide access to partner resources and markets over a multi-quarter horizon.

Consistent Positive Revenue TrendSequential revenue growth indicates improving commercial traction or service uptake despite a small base. Persistent top-line expansion supports scalability potential, enabling future operating leverage and funding capacity for clinical programs if sustained over coming quarters.

Bears Say

Negative Gross Profit And MarginsSustained negative gross profit shows the core business does not yet cover direct costs, signaling structural unprofitability. Over the medium term this undermines self-funding of R&D and commercialization, raising dependence on external financing and limiting margin improvement without material business-model changes.

Worsening Cash Burn And Poor Cash GenerationMaterially negative operating and free cash flow erode runway and increase financing needs. Persistent cash burn forces management to seek dilutive equity or costly debt, which can disrupt long-term strategy, slow program progression, and strain partner negotiations if financing options narrow.

Negative Returns On Equity Despite Lower LeverageNegative ROE indicates capital deployed is not generating shareholder value, reducing attractiveness to long-term investors. Even with lower leverage, continued losses mean retained capital doesn’t translate to returns, constraining access to patient capital needed for extended clinical development cycles.

Healios KK News

Healios to Restructure Capital to Eliminate Losses Without Diluting Shareholders

An announcement from Healios KK ( ($JP:4593) ) is now available. Healios K.K. plans to reduce portions of...

15d ago

4593

Healios Proposes New Board Slate Ahead of March Shareholders Meeting

Healios KK ( ($JP:4593) ) just unveiled an update. Healios K.K. has nominated five candidates for its Board...

15d ago

4593

Healios Issues FY2025 Results With Strong Caution on Forward-Looking Data

Healios KK ( ($JP:4593) ) has provided an update. Healios K.K. released its FY2025 financial results materials primarily...

19d ago

4593

Healios Launches Japan Arm of Global Phase 3 Trial for ARDS Stem Cell Therapy

An update from Healios KK ( ($JP:4593) ) is now available. Healios K.K. has begun preparations to initiate...

1M ago

4593

Healios Deepens Alfresa Alliance for Stem Cell Culture Supernatant Distribution in Japan

Healios KK ( ($JP:4593) ) has provided an update. Healios K.K. has signed a letter of intent with...

2M ago

4593

Healios Files Japan Trial Plan for Global Phase 3 ARDS Stem Cell Study

Healios KK ( ($JP:4593) ) has shared an announcement. Healios K.K. has submitted a clinical trial plan notification...

2M ago

4593

Healios Faces ¥120 Million Lawsuit Over Joint Research Deal but Says Business Policy Unchanged

Healios KK ( ($JP:4593) ) has issued an update. Healios K.K. disclosed that a lawsuit has been filed...

2M ago

4593

Healios K.K. Announces Key Management Changes and New Division

Healios KK ( ($JP:4593) ) has issued an announcement. Healios K.K. has announced changes in its management and...

3M ago

4593

Healios KK Advances ARDS Treatment Development with Global Study Plans

Healios KK ( ($JP:4593) ) has issued an update. Healios KK announced its development policy for HLCM051, prioritizing...

3M ago

4593

Healios K.K. Releases FY2025 Q3 Financial Results

Healios KK ( ($JP:4593) ) has shared an announcement. Healios K.K. has released its financial results for the...

4M ago

4593

4593 FAQ

What was Healios KK’s price range in the past 12 months?

Healios KK lowest stock price was ¥194.00 and its highest was ¥747.00 in the past 12 months.

What is Healios KK’s market cap?

Healios KK’s market cap is ¥56.70B.

When is Healios KK’s upcoming earnings report date?

Healios KK’s upcoming earnings report date is May 20, 2026 which is in 74 days.

How were Healios KK’s earnings last quarter?

Healios KK released its earnings results on Feb 16, 2026. The company reported ¥18.9 earnings per share for the quarter, beating the consensus estimate of ¥4.65 by ¥14.25.

Is Healios KK overvalued?

According to Wall Street analysts Healios KK’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Healios KK pay dividends?

Healios KK does not currently pay dividends.

What is Healios KK’s EPS estimate?

Healios KK’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Healios KK have?

Healios KK has 135,002,200 shares outstanding.

What happened to Healios KK’s price movement after its last earnings report?

Healios KK reported an EPS of ¥18.9 in its last earnings report, beating expectations of ¥4.65. Following the earnings report the stock price went up 4.087%.

Which hedge fund is a major shareholder of Healios KK?

Currently, no hedge funds are holding shares in JP:4593

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Healios KK

Healios KK (4593) is a biotechnology company based in Japan that focuses on the research, development, and commercialization of innovative therapies and solutions for various medical conditions. The company primarily operates in the healthcare sector, with a strong emphasis on regenerative medicine and cell therapy. Healios aims to address unmet medical needs through its core products, which include advanced treatments for neurological disorders, cancer, and other serious illnesses, leveraging cutting-edge technologies and scientific research.

Healios KK (4593) Earnings & Revenues

Historic Earnings Reports

4593 Stock 12 Month Forecast

Average Price Target

¥800.00

▲(163.16% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"217":"¥217","363":"¥363","509":"¥509","655":"¥655","801":"¥801"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":800,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥800.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":800,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥800.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":800,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥800.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[217,363,509,655,801],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,374,406.7692307692308,439.53846153846155,472.30769230769226,505.0769230769231,537.8461538461538,570.6153846153845,603.3846153846154,636.1538461538462,668.9230769230769,701.6923076923076,734.4615384615385,767.2307692307692,{"y":800,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,374,406.7692307692308,439.53846153846155,472.30769230769226,505.0769230769231,537.8461538461538,570.6153846153845,603.3846153846154,636.1538461538462,668.9230769230769,701.6923076923076,734.4615384615385,767.2307692307692,{"y":800,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,374,406.7692307692308,439.53846153846155,472.30769230769226,505.0769230769231,537.8461538461538,570.6153846153845,603.3846153846154,636.1538461538462,668.9230769230769,701.6923076923076,734.4615384615385,767.2307692307692,{"y":800,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":218,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":304,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":271,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":320,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":535,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":432,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":637,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":543,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":499,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":492,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":466,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":274,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":374,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 14</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >